本文選題：B淋巴細(xì)胞刺激因子 + B細(xì)胞來源惡性血液病��； 參考：《中國實驗血液學(xué)雜志》2017年01期

【摘要】：目的:探討B(tài)細(xì)胞來源惡性血液病中B細(xì)胞刺激因子(BLyS)的表達(dá)水平及其臨床意義。方法:自2015年3月至2016年7月我院共收入初次確診為B細(xì)胞來源惡性血液病患者57例,其中包括多發(fā)性骨髓瘤(MM)患者17例,B細(xì)胞非霍奇金淋巴瘤(B-NHL)患者40例,另有30名身體健康的志愿者作為對照組,分別記為A、B、C組。利用ELISA試劑盒測定各組患者外周血BLyS水平,化療后再次測定并進(jìn)行比較。結(jié)果:B細(xì)胞來源的惡性腫瘤患者體內(nèi)的BLyS水平較正常人明顯增高(P0.05),化療后所有患者體內(nèi)的BLyS水平均顯著降低(P0.05)。DLBCL、FL患者外周血BLyS水平明顯高于其它類型的B-NHL(P0.05),Ⅲ-Ⅳ期B-NHL患者外周血BLyS水平明顯高于Ⅰ-Ⅱ期B-NHL患者(P0.05)。結(jié)論:B細(xì)胞來源惡性血液病中BLyS表達(dá)顯著升高,且在不同組織學(xué)類型和不同分期的B-NHL患者體內(nèi)表達(dá)水平不同,提示臨床上通過檢測患者體內(nèi)BLyS表達(dá)水平,對B細(xì)胞來源惡性血液病的診斷、病情嚴(yán)重程度分期及治療具有一定指導(dǎo)意義。
[Abstract]:Objective: to investigate the expression of B cell stimulating factor (BLyS) and its clinical significance in malignant hematological diseases derived from B cells. Methods: from March 2015 to July 2016, a total of 57 patients with B-cell malignant hematologic diseases, including 17 patients with multiple myeloma (MM) and 17 patients with B cell non-Hodgkin 's lymphoma (B-NHL), were enrolled in our hospital. Another 30 healthy volunteers served as control group, respectively. The level of BLyS in peripheral blood of patients in each group was determined by Elisa kit. Results the BLyS level in the patients with malignant tumor from B cell line was significantly higher than that in the normal controls. After chemotherapy, the BLyS level in all the patients was significantly lower than that in the patients with other types of B-NHLU P0.05P, 鈪，

本文編號：2015012